...
search icon
atxs-img

Astria Therapeutics Inc, Common Stock

ATXS

NMQ

$7.5

-$0.25

(-3.23%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$423.26M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
232.54K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.71
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$7.16 L
$16.9 H
$7.5

About Astria Therapeutics Inc, Common Stock

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameATXSSectorS&P500
1-Week Return0.67%1.07%1.94%
1-Month Return-21.47%1.38%-2.02%
3-Month Return-36.22%-7.39%1.67%
6-Month Return-33.8%-6.25%6.34%
1-Year Return-0.79%1.24%25.38%
3-Year Return63.4%6.76%29.66%
5-Year Return-82.14%35.07%78.4%
10-Year Return-99.04%100.55%193.77%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue26.00K----[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit(26.00K)----[{"date":"2019-12-31","value":-2600000,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses27.09M37.44M30.36M53.50M83.03M[{"date":"2019-12-31","value":32.62,"profit":true},{"date":"2020-12-31","value":45.09,"profit":true},{"date":"2021-12-31","value":36.56,"profit":true},{"date":"2022-12-31","value":64.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(27.09M)(37.44M)(194.98M)(53.50M)(83.03M)[{"date":"2019-12-31","value":-2708800000,"profit":false},{"date":"2020-12-31","value":-3743500000,"profit":false},{"date":"2021-12-31","value":-19497600000,"profit":false},{"date":"2022-12-31","value":-5350300000,"profit":false},{"date":"2023-12-31","value":-8303000000,"profit":false}]
Total Non-Operating Income/Expense1.64M371.00K186.00K3.39M20.34M[{"date":"2019-12-31","value":8.06,"profit":true},{"date":"2020-12-31","value":1.82,"profit":true},{"date":"2021-12-31","value":0.91,"profit":true},{"date":"2022-12-31","value":16.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(26.29M)(37.30M)(194.91M)(51.83M)(72.89M)[{"date":"2019-12-31","value":-2629300000,"profit":false},{"date":"2020-12-31","value":-3730000000,"profit":false},{"date":"2021-12-31","value":-19491200000,"profit":false},{"date":"2022-12-31","value":-5183400000,"profit":false},{"date":"2023-12-31","value":-7289100000,"profit":false}]
Income Taxes(50.00K)(236.00K)(164.74M)(1.67M)15.20K[{"date":"2019-12-31","value":-328.97,"profit":false},{"date":"2020-12-31","value":-1552.73,"profit":false},{"date":"2021-12-31","value":-1083880.52,"profit":false},{"date":"2022-12-31","value":-10980.99,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(26.24M)(37.06M)(30.17M)(50.16M)(72.91M)[{"date":"2019-12-31","value":-2624300000,"profit":false},{"date":"2020-12-31","value":-3706400000,"profit":false},{"date":"2021-12-31","value":-3017300000,"profit":false},{"date":"2022-12-31","value":-5016500000,"profit":false},{"date":"2023-12-31","value":-7290619900,"profit":false}]
Income From Continuous Operations(26.29M)(37.30M)(194.91M)(51.83M)(72.89M)[{"date":"2019-12-31","value":-2629300000,"profit":false},{"date":"2020-12-31","value":-3730000000,"profit":false},{"date":"2021-12-31","value":-19491200000,"profit":false},{"date":"2022-12-31","value":-5183400000,"profit":false},{"date":"2023-12-31","value":-7289100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(26.24M)(37.06M)(30.17M)(50.16M)(72.89M)[{"date":"2019-12-31","value":-2624300000,"profit":false},{"date":"2020-12-31","value":-3706400000,"profit":false},{"date":"2021-12-31","value":-3017300000,"profit":false},{"date":"2022-12-31","value":-5016500000,"profit":false},{"date":"2023-12-31","value":-7289100000,"profit":false}]
EPS (Diluted)(14.10)(12.18)(14.31)(3.63)(2.42)[{"date":"2019-12-31","value":-1410,"profit":false},{"date":"2020-12-31","value":-1218,"profit":false},{"date":"2021-12-31","value":-1431,"profit":false},{"date":"2022-12-31","value":-363,"profit":false},{"date":"2023-12-31","value":-242,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ATXS
Cash Ratio 21.90
Current Ratio 22.38

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ATXS
ROA (LTM) -22.72%
ROE (LTM) -38.03%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ATXS
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ATXS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.72
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Astria Therapeutics Inc share price today?

Astria Therapeutics Inc (ATXS) share price today is $7.5

Can Indians buy Astria Therapeutics Inc shares?

Yes, Indians can buy shares of Astria Therapeutics Inc (ATXS) on Vested. To buy Astria Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATXS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Astria Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Astria Therapeutics Inc (ATXS) via the Vested app. You can start investing in Astria Therapeutics Inc (ATXS) with a minimum investment of $1.

How to invest in Astria Therapeutics Inc shares from India?

You can invest in shares of Astria Therapeutics Inc (ATXS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ATXS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Astria Therapeutics Inc shares
What is Astria Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Astria Therapeutics Inc (ATXS) is $16.9. The 52-week low price of Astria Therapeutics Inc (ATXS) is $7.16.

What is Astria Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Astria Therapeutics Inc (ATXS) is

What is Astria Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Astria Therapeutics Inc (ATXS) is 1.72

What is Astria Therapeutics Inc dividend yield?

The dividend yield of Astria Therapeutics Inc (ATXS) is 0.00%

What is the Market Cap of Astria Therapeutics Inc?

The market capitalization of Astria Therapeutics Inc (ATXS) is $423.26M

What is Astria Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Astria Therapeutics Inc is ATXS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top